Key result
Perioperative landiolol cuts postoperative atrial fibrillation risk ~67% compared with controls.
Why the study?
Atrial fibrillation is the most common arrhythmic complication after cardiac surgery, and the efficacy of landiolol in preventing new-onset AF after cardiac surgery has been studied but not definitively established.
Does landiolol reduce the occurrence of new-onset atrial fibrillation in patients after cardiac surgery?
Meta-Analysis
Does landiolol reduce the occurrence of new-onset atrial fibrillation in patients after cardiac surgery?
Relative Risk: 0.33 (95% CI 0.23–0.48)
p-value: p=<0.00001
Perioperative landiolol administration safely and effectively reduces the incidence of new-onset atrial fibrillation following cardiac surgery.
Supports perioperative landiolol to prevent post-cardiac surgery AF; confirms substantial risk reduction in meta-analysis of trials.
BackgroundAtrial fibrillation (AF) is the most common arrhythmic complication after cardiac surgery. Several studies have compared the efficacy of landiolol and placebo or other agents in preventing new‐onset AF in patients after cardiac surgery. In this study, we conducted a meta‐analysis to determine whether landiolol is effective in preventing new‐onset AF after cardiac surgery.Methods and ResultsFive randomized controlled trials and two retrospective analyses were included in this study. The clinical outcomes of interest were the occurrence of AF after cardiac surgery and major complications. Meta‐analysis was performed using RevMan 5.0.18 software, and pooled estimates of the effect were reported as risk ratios (RR) with 95% confidence intervals (CI). The results of this meta‐analysis indicate that landiolol is significantly associated with a decreased risk of occurrence of AF after cardiac surgery (RR = 0.33; 95% CI: 0.23–0.48; P < 0.00001) and is not associated with an increased risk of major complications (RR = 0.79; 95% CI: 0.43–1.45; P = 0.45) compared with the control group.ConclusionLandiolol administration in the perioperative period can reduce the occurrence of AF after cardiac surgery without increasing the risk of major complications. It can be used to prevent new‐onset AF safely after cardiac surgery.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2014) conducted a meta-analysis in Atrial fibrillation after cardiac surgery. Landiolol vs. Placebo or other agents was evaluated on Occurrence of atrial fibrillation after cardiac surgery (RR 0.33, 95% CI 0.23-0.48, p=<0.00001). Perioperative administration of landiolol significantly decreased the risk of new-onset atrial fibrillation after cardiac surgery compared with controls (RR 0.33; 95% CI 0.23-0.48; P<0.00001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: